外泌体（Exosome）是由细胞分泌至胞外的具有生理功能的囊泡样小体，有望成为诊断非小细胞肺癌（NSCLC）的新型标志物。我们前期研究发现，NSCLC分泌的exosome中p62蛋白的水平在NSCLC患者血浆和健康对照中差异显著，且exosome p62蛋白能被巨噬细胞摄取，并促进肺肿瘤生长；实验结果和生物信息学分析预测exosome p62蛋白可能参与调控巨噬细胞表型、功能和自噬。据此提出假设：血浆exosome p62蛋白是NSCLC诊断、疗效监测和预后判断的新型肿瘤标志物；NSCLC细胞p62蛋白通过exosome进入肿瘤微环境中的巨噬细胞，调控它的一系列功能转化促进NSCLC的生长。拟通过临床标本及体内外实验全面系统研究exosome p62蛋白作为NSCLC标志物的临床价值；明确exosome p62蛋白调控巨噬细胞的作用及机制，为NSCLC的诊断和治疗提供新的策略。

Exosomes are endogenous nano-vesicles secreted by cells with various physiological functions that have emerged as a new tumor biomarker for non-small cell lung cancer (NSCLC). We previously reported that the expression level of NSCLC secreted exosomal p62 protein (NSCLC-Exos-p62) in plasma from NSCLC patients was significantly different from healthy controls, that NSCLC-Exos-p62 can be taken up by macrophages, promoting lung cancer growth, and that research data and bioinformatic analysis indicated that NSCLC-Exos-p62 may regulate phenotype, function, and autophagy of macrophages. Therefore it is hypothesized that plasma exosomal p62 protein can be used as a tumor biomarker for diagnosis, monitoring, and prognosis of NSCLC, and that NSCLC-Exos-p62 can enter into macrophages of the microenvironment and regulate their function, promoting growth of NSCLC. This study is designed to investigate the potential clinical value of NSCLC-Exos-p62 as a newly identified tumor biomarker, and to determine the effect of NSCLC-Exos-p62 on macrophages, using clinical sample complemented with in vivo and in vitro experiments. This study will provide a new strategy for the diagnosis and therapy of NSCLC.